Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines
Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines
About this item
Full title
Author / Creator
Sasaki, H , Hayakawa, J , Terai, Y , Kanemura, M , Tanabe-Kimura, A , Kamegai, H , Seino-Noda, H , Ezoe, S , Matsumura, I , Kanakura, Y , Sakata, M , Tasaka, K and Ohmichi, M
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Although there is growing evidence that estrogens promote tumor progression in epithelial ovarian cancer, the molecular mechanisms accounting for this are still unclear. Selective estrogen receptor modulators (SERMs) mimic estrogen action in certain tissues while opposing it in others. The molecular mechanisms of the effects of SERMs such as raloxi...
Alternative Titles
Full title
Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_69137502
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_69137502
Other Identifiers
ISSN
0950-9232
E-ISSN
1476-5594
DOI
10.1038/sj.onc.1210926
